American Journal of Infectious Diseases and Microbiology
ISSN (Print): 2328-4056 ISSN (Online): 2328-4064 Website: Editor-in-chief: Maysaa El Sayed Zaki
Open Access
Journal Browser
American Journal of Infectious Diseases and Microbiology. 2013, 1(3), 50-58
DOI: 10.12691/ajidm-1-3-3
Open AccessArticle

Development of Sequence Based Molecular Diagnostic Test to Evaluate MDR and XDR in M. tuberculosis Patients from Western India

Pravin Potdar1, and Prerna Thakur1

1Department of Molecular Medicine & Biology, Jaslok hospital & Research Centre, Maharashtra, India

Pub. Date: June 12, 2013

Cite this paper:
Pravin Potdar and Prerna Thakur. Development of Sequence Based Molecular Diagnostic Test to Evaluate MDR and XDR in M. tuberculosis Patients from Western India. American Journal of Infectious Diseases and Microbiology. 2013; 1(3):50-58. doi: 10.12691/ajidm-1-3-3


Globally, Tuberculosis is the most distress disease which remains as a major challenge from the standpoint of diagnosis, detection of drug resistance, and treatment. The increasing knowledge in molecular biology techniques has improved our understanding of the molecular mechanisms of drug resistance for the major first and second-line anti- tubercular drugs. Thus, rapid and accurate diagnosis of Tuberculosis would improve patient care and limit its transmission. This study is aimed to identify mutations in drug resistance genes of first and second line drugs against Mycobacterium tuberculosis by using polymerase chain reaction (PCR) and DNA sequencing methods. This study involves sputum samples of 20 patients diagnosed to have pulmonary tuberculosis. The genomic DNA from clinical isolates was isolated using simple boiling method. PCR amplification and DNA sequencing were performed for katG, inhA, ndh, kasA, pncA, embB, rrs, rpsL, rpoB, gyrA, gyrB and thyA genes. Sequence analysis was done using Bioedit, a bioinformatics tool. The isolates of Mycobacterium tuberculosis from western part of India were analyzed by DNA sequencing revealed total 29 mutations in first line drugs. Out of them, 5(25%) in rpoB at codon 516 and 531, 6(30%) in katG at codon 315, 8(40%) in rpsL at codon 43 & 88, 3(15%) in embB at codon 306 and 7(35%) in pncA at codon 195.No mutations in inhA, ndh, kasA and rrs genes were observed in our study. In the second line drugs, 2(10%) at codon 90 & 100% mutations at codon 95 in gyrA gene, and no mutation in gyrB and thyA genes were observed.

Mycobacterium tuberculosis PCR DNA sequencing MDR XDR

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit


Figure of 9


[1] WHO (2009) Global tuberculosis control: a short update to the 2009 report
[2]  Flynn, J.L Chan: Tuberculosis: Latency and Reactivation. J Infect. Immun. 69, 4195-4201, 2001.
[3]  Clark-Curtiss, J.E. Haydel, S.E; Molecular genetics of Mycobacterium tuberculosis pathogenesis. Annu. Rev. Microbiol. 57, 517-549, 2003.
[4]  Maartens, G.; Wilkinson, R.J: Tuberculosis Lancet 370, 2030-2043, 2007.
[5]  Corbett, E.L.; Watt, C.J.; Walker, N.; Maher, D.; Williams, B.G.; Raviglione, M.C.; Dye, C, The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch. Intern.Med. 163, 1009-1021, 2003.
[6]  Steenken,W.,and Wolinsky,E,Amer.Rev.Tuberc.,58,353,1948.
[7]  Cole, S. T., Brosch, R., Parkhill, J. & 39 other authors .Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence., Nature 393, 537-544, 1998.
[8]  Escalante, P., Ramaswamy, S., Sanabria, H., Soini, H., Pan, X., Valiente Castillo, O. &Musser, J.M.: Genotypic characterization of drug-resistant Mycobacterium tuberculosis isolates from Peru. Tuber Lung, Dis 79, 111-118, 1998.
[9]  Soini H and Musser J: Molecular Diagnosis of Mycobacteria, Clinical Chemistry 47:5 809-814, 2001.
[10]  Hillemann D,Weizenegger M, Kubica,T,Richter E & Niemann S,:Use of the genotype MTBDR assay for rapid detection of rifampin and isoniazid in Mycobacterium tuberculosis complex isolates, J Clin Microbio 43,3699-703, 2005.
[11]  Kocagoz T; Yilmaz E,Kocagzoz S,Hayran M,Sachedeva M and Chambers H:Detection of Mycobacterium tuberculosis in sputum samples by Polymerase Chain Reaction using a simplified procedure, Journal of Clinical Microbiology ,vol 31,No.6 p 1435-1438, June 1993.
[12]  Mani.C, Selvakumar.N, Narayanan.S and. Narayanan.P: Mutations in the rpoB Gene of Multidrug-Resistant Mycobacterium tuberculosis Clinical Isolates from India, J. Clin. Microbiol, 39(8):2987, 2001
[13]  Lu J, Jiang S, Ye S, Hu Z; Sequence analysis on drug- resistant rpoB gene of Mycobacterium tuberculosis L-form of isolated from pneumoconiosis workers. J. Med. Coll PLA 24: 223-22, 2009.
[14]  Abdelaal A, El-Ghaffar HA, Mohammad HEZ, El mashad N, Badran E, Fathy A: Genotypic detection of rifampicin and isoniazid resistant Mycobacterium tuberculosis strains by DNA sequencing: a randomized trial. Annals of Clinical Microbiology and Antimicrobials 8:1-8, 2009.
[15]  Ramaswamy, S. and Musser, J.M: Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis, Tuber Lung Dis. 79, 3-29, 1998.
[16]  Basso, L.A. and Blanchard, J.S: Resistance to antitubercular drugs. Adv. Exp. Med. Biol. 456, 115-144, 1998.
[17]  VadwaiV, Ajbanj K, Jose M, Vineeth VP, Nikam C, Deshmukh M, Shetty A, Soman R, Rodrigues C: Can inhA mutation predict ethionamide resistance? Int J Tuberc Lung Dis. 2013 Jan.
[18]  Rozwarski, D.A., Grant, G.A., Barton, D.H., Jacobs, W.R., and Sacchettini, J.C, Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Science 279, 98-102, 1998.
[19]  Miesel, L., Weisbrod, T.R., Marcinkeviciene, J.A., Bittman, R., and Jacobs, W.R.: NADH dehydrogenase defects confer isoniazid resistance and conditional lethality in Mycobacterium smegmatis. J. Bacteriol. 180, 2459-2467, 1998.
[20]  Lee, A.S., Lim, I.H., Tang, L.L., Telenti, A., and Wong, S.Y: Contribution of kasA analysis to detection of isoniazid-resistant Mycobacterium tuberculosis in Singapore. Antimicrob Agents Chemother, 43 2087-2089, 1999.
[21]  Piatek, A.S., Telenti, A., Murray, M.R., el Hajj, H., Jacobs, W.R., Jr., Kramer, F.R., and Alland, D:Genotypic analysis of Mycobacterium tuberculosis in two distinct populations using molecular beacons: implications for rapid susceptibility testing. Antimicrob. Agents Chemotherapy. 44, 103-110, 2000.
[22]  Unissa N, Selvakumar N,Narayanan S,Narayanan PR Molecular analysis of isoniazid resistant clinical isolates of Mycobacterium tuberculosis from India,.Int J Antimicro Agents, Jan 2008.
[23]  Slayden, R.A. and Barry, C.E, III: The genetics and biochemistry of isoniazid resistance in Mycobacterium tuberculosis. Microbes. Infect. 2, 659-669, 2000.
[24]  Hernando M, Brimacombe M, Bobadilla M, Cavatore M: Population Genetics Study of Isoniazid Resistance Mutations and Evolution of Multidrug-Resistant Mycobacterium tuberculosis, Antimicrobial Agents and Chemotherapy, p. 2640-2649, Aug. 2006.
[25]  Gupta A, Prakash P, Singh S,and Anupurba S: Rapid Genotypic Detection of rpoB and katG Gene Mutations in Mycobacterium tuberculosis Clinical Isolates from Northern India as Determined by MAS-PCR, Journal of Clinical Laboratory Analysis 27: 31-37 2013.
[26]  Jureen P, Werngren J, Toro J, and Hoffner S: Pyrazinamide Resistance and pncA Gene Mutations in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, Vol. 52, No. 5, p. 1852-1854, 1998.
[27]  Prabhu S, Muthuraj M, Sridhar J, Manupriya S and Usharani B: Rapid Detection of PncA Mutations in Pyrazinamide-Resistant Mycobacterium tuberculosis Clinical isolates, European Journal of Applied Sciences 1 (2): 20-25, 2009.
[28]  Jain M, Mondal R, Srivastava S, Prasad R, Singh K & Ahuja R: Novel mutations in embB gene of Ethambutol resistant isolates of Mycobacterium tuberculosis: A preliminary report, Indian J Med Res 128, pp 634-639, November 2008.
[29]  Shinnick T,Posey J Starks A, Gumusboga A, Plikaytis B: Important Molecular Indicator of Mutations at embB Codon 306 Are an Ethambutol Resistance in Mycobacterium tuberculosis, Antimicrob. Agents Chemother., 53(3):1061, 2009.
[30]  Zhenling C, Wang J, Lu J, Huang X and Zhongyi H: Association of mutation patterns in gyrA/B genes and ofloxacin resistance levels in Mycobacterium tuberculosis isolates from East China in 2009, BMC Infectious Diseases, 11:78, 2011.
[31]  Cheng A, Yew W,Chan E, Chin M, Hui M, and Chan R: Multiplex PCR Amplimer Conformation Analysis for Rapid Detectionof gyrA Mutations in Fluoroquinolone-Resistant Mycobacterium tuberculosis Clinical Isolates, Antimicrobial Agents and Chemotherapy, Vol. 48, No. 2, p. 596-601, Feb. 2004.
[32]  Lau R, Ho P, Kao R, Yew W, Lau T,Cheng V, Yuen K, Tsui S,Chen X, and Yam W: Molecular Characterization of Fluoroquinolone Resistance in Mycobacterium tuberculosis: Functional Analysis of gyrA Mutation at Position 74, Antimicrobial Agents and Chemotherapy, Vol. 55, No. 2, p. 608-614, Feb. 2011.
[33]  Feuerriegel S, Ko¨ser C, Tru¨be L, Archer J, Gerdes S, Richter E, and Niemann S: Thr202Ala in thyA Is a Marker for the Latin American Mediterranean Lineage of the Mycobacterium tuberculosis Complex Rather than Para-Amino salicylic Acid Resistance, Antimicrobial Agents and Chemotherapy, Vol. 54, No. 11, p. 4794-4798 Nov. 2010.